İnfektif Endokardit: Güncel Bilgiler
Yıl: 2015 Cilt: 28 Sayı: 2 Sayfa Aralığı: 46 - 67 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022
İnfektif Endokardit: Güncel Bilgiler
Öz: İnfektif endokardit (İE), çok uzun yıllardan beri bilinen bir has-Although infective endocarditis (IE) has been recognized for talık olmasına ve tanı ve tedavisinde birçok gelişmeler sağlanyears and despite the advances in the diagnosis and treatment, masına karşın, tüm tıbbi olanaklara erişimin mümkün olduğu it is associated with a mortality rate as high as 20% even in gelişmiş ülkelerde bile %20 gibi yüksek bir mortalite hızı sergiler. developed countries in which IE cases have more access to new Ülkemizde ise bu hız %30'u bulmaktadır. İE'nin tanısı, tedavisi diagnostic technologies and surgical facilities. The mortality ve önlenmesi konusunda yayımlanmış çok fazla sayıda rehber rate is even higher in Turkey and is reported to be 30%. There vardır. Ancak günlük klinik pratikte, bu rehberlere uyum konu-are many guidelines on the management of IE, but compliance sunda önemli sorunlar yaşanmakta, bu da hasta prognozunu with these guidelines is poor in daily clinical practice. A stanolumsuz yönde etkilemektedir. İE'li hastaların tanı ve tedavisi dardised strategy based on a local consensus of IE among iniçin infeksiyon hastalıkları ve klinik mikrobiyoloji, kardiyoloji ve fectious diseases and clinical microbiology specialists, cardiolokardiyovasküler cerrahi uzmanlarının birlikte çalışması (İE ekibi) gists and cardiac surgeons (i.e., infective endocarditis team) can ve ortak bir yaklaşım oluşturması, başvurulan hekimden bağımresult in reproducibility of treatment for all patients regardless sız olarak, her hastaya standard bir tedavi uygulanmasını sağla-of the attending physician. In this review, epidemiology, etiolyabilir. Bu derlemede, İE epidemiyolojisi, etkenleri, tanısı, tedaogy, diagnosis and prevention of IE in Turkey and other parts visi ve önlenmesi konusunda ülkemizde ve dünyadaki mevcut of the world were discussed in the light of current guidelines durum, güncel yayınlar ve rehberler eşliğinde değerlendirilmiş, and recent research; and some recommendations were made İE'li hasta bakımının daha iyi hale getirilebilmesi için öneriler to improve the management of IE.sunulmuştur.
Anahtar Kelime: Konular:
Infective Endocarditis: An Update
Öz: Although infective endocarditis (IE) has been recognized for years and despite the advances in the diagnosis and treatment, it is associated with a mortality rate as high as 20% even in developed countries in which IE cases have more access to new diagnostic technologies and surgical facilities. The mortality rate is even higher in Turkey and is reported to be 30%. There are many guidelines on the management of IE, but compliance with these guidelines is poor in daily clinical practice. A standardised strategy based on a local consensus of IE among infectious diseases and clinical microbiology specialists, cardiologists and cardiac surgeons (i.e., infective endocarditis team) can result in reproducibility of treatment for all patients regardless of the attending physician. In this review, epidemiology, etiology, diagnosis and prevention of IE in Turkey and other parts of the world were discussed in the light of current guidelines and recent research; and some recommendations were made to improve the management of IE.
Anahtar Kelime: Konular:
Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık
- Fowler VG, Scheld WM, Bayer AS. Endocarditis and intravascular infections. In: Bennett JE, Dolin R, Blaser MJ, eds. Mandell, Doug- las, and Bennett's Principles and Practice of Infectious Diseases. 8th ed. Philadelphia: Elsevier Saunders, 2015: 990-1028.
- Starkebaum V, Durack D, Beeson P. The "incubation period" of su- bacute bacterial endocarditis. Yale J Biol Med. 1977; 50(1): 49-58.
- Issa VS, Fabri J Jr, Pomerantzeff PM, Grinberg M, Pereira-Barreto AC, Mansur AJ. Duration of symptoms in patients with infective endocarditis. Int J Cardiol. 2003; 89(1): 63-70. [CrossRef]
- Habib G, Hoen B, Tornos P, et al. Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): the Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by the European Society of Clinical Microbio- logy and Infectious Diseases (ESCMID) and the International So- ciety of Chemotherapy (ISC) for Infection and Cancer. Eur Heart J. 2009; 30(19): 2369-413. [CrossRef]
- Ben-Ami R, Giladi M, Carmeli Y, Orni-Wasserlauf R, Siegman-Igra Y. Hospital-acquired infective endocarditis: should the definition be broadened? Clin Infect Dis. 2004; 38(6): 843-50. [CrossRef]
- Hoen B, Duval X. Clinical practice. Infective endocarditis. N Eng J Med. 2012; 368(15): 1425-33. [CrossRef]
- Thuny F, Grisoli D, Collart F, Habib G, Raoult D. Management of infective endocarditis: challenges and perspectives. Lancet. 2012; 379(9819): 965-75. [CrossRef]
- Murdoch, DR, Corey GR, Hoen B, et al. Clinical presentation, eti- ology, and outcome of infective endocarditis in the 21st Century. The International Collaboration on Endocarditis-Prospective Co- hort Study. Arch Intern Med. 2009; 169(5): 463-73. [CrossRef]
- Selton-Suty C, Célard M, Le Moing V, et al. Preeminence of Staph- ylococcus aureus in infective endocarditis: a 1-year population- based survey. Clin Infect Dis. 2012; 54(9): 1230-9. [CrossRef]
- Çetinkaya Y, Akova M, Akalın HE, et al. A retrospective review of 228 episodes of infective endocarditis where rheumotic valvular disease still common. Int J Antimicrob Agents. 2001; 18(1): 1-7. [CrossRef]
- Leblebicioğlu H, Yılmaz H, Taşova Y, et al. Characteristics and analysis of risk factors for mortality in infective endocarditis. Eur J Epidemiol. 2006; 21(1): 25-31. [CrossRef]
- Tuğcu A, Yıldırımtürk Ö, Baytaroğlu C, et al. Clinical spectrum, presentation, and risk factors for mortality in infective endocar- ditis: a review of 68 cases at a tertiary care center in Turkey. Türk Kardiyol Dern Arş. 2009; 37(1): 9-18.
- Elbey MA. Akdağ A, Kalkan MA, et al. A multicenter study on experience of 13 tertiary hospitals in Turkey in patients with in- fective endocarditis. Anadolu Kardiyol Derg. 2013; 13(6): 523-7. [CrossRef]
- Sucu M, Davutoğlu V, Özer O, Aksoy M. Epidemiological, clinical and microbiological profile of infective endocarditis in a tertiary hospital in the South-East Anatolia Region. Türk Kardiyol Dern Arş. 2010; 38(2): 107-11.
- Şimşek-Yavuz S, Şensoy A, Kaşıkcıoğlu H, et al. Infective endo- carditis in Turkey: aetiology, clinical features, and analysis of risk factors for mortality in 325 cases. Int J Infect Dis. 2015; 30: 106-14. [CrossRef]
- Demirbağ R, Sade LE, Aydın M, Bozkurt A, Acartürk E. The Tur- kish registry of heart valve disease. Türk Kardiyol Dern Arş. 2013; 41(1): 1-10. [CrossRef]
- Tibazarwa KB, Volmink JB, Mayosi BM. Incidence of acute rheu- matic fever in the world: a systematic review of population-based studies. Heart. 2008; 94(12): 1534-40. [CrossRef]
- Orün UA, Ceylan O, Bilici M, et al. Acute rheumatic fever in the Central Anatolia Region of Turkey: a 30-year experience in a single center. Eur J Pediatr 2012; 171(2): 361-8. [CrossRef]
- Marijon E, Mirabel M, Celermajer DS, Jouven X. Rheumatic heart disease. Lancet. 2012; 379(9819): 953-64. [CrossRef]
- Sandoe JA, Barlow G, Chambers JB, et al. Guidelines for the diagnosis, prevention and management of implantable cardiac electronic device infection. Report of a joint Working Party project on behalf of the British Society for Antimicrobial Chemotherapy (BSAC, host organization), British Heart Rhythm Society (BHRS), British Cardiovascular Society (BCS), British Heart Valve Society (BHVS) and British Society for Echocardiography (BSE). J Anti- microb Chemother. 2015; 70(2): 325-59. [CrossRef]
- Baddour LM, Epstein AE, Erickson CC, et al. Update on cardiovas- cular implantable electronic device infections and their manage- ment: a scientific statement from the American Heart Associati- on. Circulation. 2010; 121(3): 458-77. [CrossRef]
- Olmos C, Vilacosta İ, Fernández C, et al. Comparison of clinical features of left-sided infective endocarditis involving previously normal versus previously abnormal valves. Am J Cardiol. 2014; 114(2): 278-83. [CrossRef]
- Fowler VG, Miro JM, Hoen B, et al. Staphylococcus aureus en- docarditis: a consequence of medical progress. JAMA. 2005; 293(24): 3012-21. [CrossRef]
- Chu VH, Cabell CH, Abrutyn E, et al. Native valve endocarditis due to coagulase-negative staphylococci: report of 99 episodes from the International Collaboration on Endocarditis Merged Databa- se. Clin Infect Dis. 2004; 39(10): 1527-30.
- Liu PY, Huang YF, Tang CW, et al. Staphylococcus lugdunensis in- fective endocarditis: a literature review and analysis of risk fac- tors. J Microbiol Immunol Infect. 2010; 43(6): 478-84. [CrossRef]
- Emmerson AM. Eykyn S. Streptococcus mutans endocarditis--a trap for the unwary. Br Med J. 1977; 1(6065): 905. [CrossRef]
- Schelenz S, Page AJ, Emmerson AM. Streptococcus mutans en- docarditis: beware of the 'diphtheroid'. J R Soc Med. 2005; 98(9): 420-1. [CrossRef]
- Şimşek-Yavuz S, Eren M, Yavuz A, et al. İnfektif endokardit: 58 olgunun değerlendirilmesi. Klimik Derg. 2003; 16(2): 55-62.
- Schlegel L, Grimont F, Ageron E, Grimont PA, Bouvet A. Reappraisal of the taxonomy of the Streptococcus bovis/Streptococcus equinus complex and related species: description of Streptococcus gallolyti- cus subsp. gallolyticus subsp. nov., S. gallolyticus subsp. macedoni- cus subsp. nov. and S. gallolyticus subsp. pasteurianus subsp. nov. Int J Syst Evol Microbiol. 2003; 53(Pt3): 631-45. [CrossRef]
- Klein RS, Catalano MT, Edberg SC, Casey JI, Steigbigel NH. Strep- tococcus bovis septicemia and carcinoma of the colon. Ann In- tern Med. 1979; 91(4): 560-2. [CrossRef]
- Boleij A, Muytjens CM, Bukhari SI, et al. Novel clues on the specific association of Streptococcus gallolyticus subsp gallolyticus with colorectal cancer. J Infect Dis. 2011; 203(8): 1101-9. [CrossRef]
- Boleij A, van Gelder MM, Swinkels DW, Tjalsma H. Clinical impor- tance of Streptococcus gallolyticus infection among colorectal cancer patients: systematic review and meta-analysis. Clin Infect Dis 2011; 53(9): 870-8. [CrossRef]
- Corredoira-Sánchez J, García-Garrote F, Rabuñal R, et al. Associa- tion between bacteremia due to Streptococcus gallolyticus subsp. gallolyticus (Streptococcus bovis I) and colorectal neoplasia: a ca- se-control study. Clin Infect Dis. 2012; 55(4): 491-6. [CrossRef]
- Chirouze C, Athan E, Alla F, et al. Enterococcal endocarditis in the beginning of the 21st century: analysis from the International Col- laboration on Endocarditis-Prospective Cohort Study. Clin Micro- biol Infect. 2013; 19(12): 1140-7. [CrossRef]
- Anderson DJ, Olaison L, McDonald JR, et al. Enterococcal prost- hetic valve infective endocarditis: report of 45 episodes from the International Collaboration on Endocarditis-merged database. Eur J Clin Microbiol Infect Dis. 2005; 24(10): 665-70. [CrossRef]
- Spies C, Madison JR, Schatz IJ. Infective endocarditis in patients with end-stage renal disease: clinical presentation and outcome. Arch Intern Med. 2004; 164(1): 71-5. [CrossRef]
- Miro JM, Pericas JM, del Rio A; Hospital Clinic Endocarditis Study Group. A new era for treating Enterococcus faecalis endocarditis: ampicillin plus short-course gentamicin or ampicillin plus ceftriaxo- ne: that is the question Circulation. 2013; 127(17): 1763-6. [CrossRef]
- Houpikian P, Raoult D. Blood culture-negative endocarditis in a reference center: etiologic diagnosis of 348 cases. Medicine (Bal- timore). 2005; 84(3): 162-73. [CrossRef]
- Özdemir S. Nadir Rastlanan Enfektif Endokardit Etkenlerinin Araştırılması: HACEK Grubu Mikroorganizmalar, Chlamydophila pneumoniae, Coxiella Türleri ve Bartonella Türleri [Doktora Tezi]. İstanbul: İstanbul Üniversitesi Sağlık Bilimleri Enstitüsü Tıbbi Mik- robiyoloji Anabilim Dalı, 2012.
- Baddley JW, Benjamin DK Jr, Patel M, et al. Candidainfectiveen- docarditis. Eur J Clin Microbiol Infect Dis. 2008; 27(7): 519-29. [CrossRef]
- Ellis ME, Al-Abdely H, Sandridge A, Greer W, Ventura W. Fun- gal endocarditis: evidence in the world literature, 1965-1995. Clin Infect Dis. 2001; 32(1): 50-62. [CrossRef]
- Fernández Guerrero ML, Álvarez B, Manzarbeitia F, Renedo G. Infec- tive endocarditis at autopsy: a review of pathologic manifestations and clinical correlates. Medicine (Baltimore). 2012; 91(3): 152-64. [CrossRef]
- Nunes MC, Gelape CL, Ferrari TC. Profile of infective endocardi- tis at a tertiary care center in Brazil during a seven-year period: prognostic factors and in-hospital outcome. Int J Infect Dis. 2010; 14(5): e394-8. [CrossRef]
- Math RS, Sharma G, Kothari SS, et al. Prospective study of infec- tive endocarditis from a developing country. Am Heart J. 2011; 162(4): 633-8. [CrossRef]
- Garg N, Kandpal B, Garg N, et al. Characteristics of infective endocar- ditis in a developing country-clinical profile and outcome in 192 Indi- an patients, 1992-2001. Int J Cardiol. 2005; 98(2): 253-60. [CrossRef]
- Tariq M, Alam M, Munir G, Khan MA, Smego RA Jr. Infective en- docarditis: a five-year experience at a tertiary care hospital in Pa- kistan. Int J Infect Dis. 2004; 8(3): 163-70. [CrossRef]
- Letaief A, Boughzala E, Kaabia N, et al. Epidemiology of infective endocarditis in Tunisia: a 10-year multicenter retrospective study. Int J Infect Dis. 2007; 11(5): 430-3. [CrossRef]
- Gould FK, Denning DW, Elliott TS, et al. Guidelines for the diagno- sis and antibiotic treatment of endocarditis in adults: a report of the Working Party of the British Society for Antimicrobial Chemothe- rapy. J Antimicrob Chemother. 2012; 67(2): 269-89. [CrossRef]
- Raoult D, Casalta JP, Richet H, et al. Contribution of systematic serological testing in diagnosis of infective endocarditis. J Clin Microbiol. 2005; 43(10): 5238-42. [CrossRef]
- Breitkopf C, Hammel D, Scheld HH, Peters G, Becker K. Impact of a molecular approach to improve the microbiological diagnosis of infective heart valve endocarditis. Circulation. 2005; 111(11): 1415-21. [CrossRef]
- Rovery C, Greub G, Lepidi H, et al. PCR detection of bacteria on cardiac valves of patients with treated bacterial endocarditis. J Clin Microbiol. 2005; 43(1): 163-7.
- Muñoz P, Bouza E, Marín M, et al. Heart valves should not be rou- tinely cultured. J Clin Microbiol. 2008; 46(9): 2897-91. [CrossRef]
- Lepidi H, Coulibaly B, Casalta JP, Raoult D. Autoimmunohistoc- hemistry: a new method for the histologic diagnosis of infective endocarditis. J Infect Dis. 2006; 193(12): 1711-7. [CrossRef]
- Syed FF, Millar BC, Prendergast BD. Molecular technology in con- text: a current review of diagnosis and management of infective endocarditis. Prog Cardiovasc Dis. 2007; 50(3): 181-97. [CrossRef]
- Fenollar F, Goncalves A, Esterni B, et al. A serum protein signa- ture with high diagnostic value in bacterial endocarditis: results from a study based on surface-enhanced laser desorption/ioniza- tion time-of-flight mass spectrometry. J Infect Dis. 2006; 194(10): 1356-66. [CrossRef]
- Fournier PE, Thuny F, Richet H, et al. Comprehensive diagnostic stra- tegy for blood culture-negative endocarditis: a prospective study of 819 new cases. Clin Infect Dis. 2010; 51(2): 131-40. [CrossRef]
- Thuny F, Fournier PE, Casalta JP, et al. Investigation of blood cul- ture-negative early prosthetic valve endocarditis reveals high pre- valence of fungi. Heart. 2010; 96(10): 743-7. [CrossRef]
- Fournier PE, Thuny F, Grisoli D, et al. A deadly aversion to pork. Lancet. 2011; 377(9776): 1542. [CrossRef]
- Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis: di- agnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation. 2005; 111(23): 394-434. [CrossRef]
- Liu YW, Tsai WC, Lin CC, et al. Usefulness of real-time three-di- mensional echocardiography for diagnosis of infective endocar- ditis. Scand Cardiovasc J. 2009; 43(5): 318-23. [CrossRef]
- Feuchtner GM, Stolzmann P, Dichtl W, et al. Multislice computed tomography in infective endocarditis: comparison with transe- sophageal echocardiography and intraoperative findings. J Am Coll Cardiol. 2009; 53(5): 436-44. [CrossRef]
- Van Riet J, Hill EE, Gheysens O, et al. (18)F-FDG PET/CT for early de- tection of embolism and metastatic infection in patients with infec- tive endocarditis. Eur J Nucl Med Mol Imaging. 2010; 37(6): 1189-97. [CrossRef]
- Saby L, Laas O, Habib G, et al. Positron emission tomography/com- puted tomography for diagnosis of prosthetic valve endocarditis: increased valvular 18F-fluorodeoxyglucose uptake as a novel ma- jor criterion. J Am Coll Cardiol. 2013; 61(23): 2374-82. [CrossRef]
- Cooper HA, Thompson EC, Laureno R, et al. Subclinical brain embolization in left-sided infective endocarditis: results from the evaluation by MRI of the brains of patients with left-sided intra- cardiac solid masses (EMBOLISM) pilot study. Circulation. 2009; 120(7): 585-91. [CrossRef]
- Fernández-Hidalgo N, Almirante B, Tornos P, et al. Prognosis of left-sided infective endocarditis in patients transferred to a terti- ary-care hospital--prospective analysis of referral bias and influ- ence of inadequate antimicrobial treatment. Clin Microbiol Infect. 2011; 17(5): 769-75. [CrossRef]
- Leibovici L. Aminoglycoside-containing antibiotic combinations for the treatment of bacterial endocarditis: an evidence-based appro- ach. Int J Antimicrob Agents. 2010; 36(Suppl. 2): S46-9. [CrossRef]
- Prabhu RM, Piper KE, Baddour LM, Steckelberg JM, Wilson WR, Patel R. Antimicrobial susceptibility patterns among viridans group streptococcal isolates from infective endocarditis patients from 1971 to 1986 and 1994 to 2002. Antimicrob Agents Chemot- her. 2004; 48(11): 4463-5. [CrossRef]
- Berzeg Deniz D, Şimşek Yavuz S, Öcalmaz MŞ, Eren-Şensoy A, Er- türk A, Çeken S. Penisilin G: unutmak için çok mu erken? [Özet]. In: Timurkaynak F, Şimşek-Yavuz S, eds. XVII. Türk Klinik Mikrobiyo- loji ve İnfeksiyon Hastalıkları Kongresi (25-29 Mart 2015, Antalya) Kitabı. İstanbul: Türk Klinik Mikrobiyoloji ve İnfeksiyon Hastalıkları Derneği, 2015: 212.
- Dahl A, Rasmussen RV, Bundgaard H, et al. Enterococcus faecalis infective endocarditis: a pilot study of the relationship between duration of gentamicin treatment and outcome. Circulation. 2013; 127(17): 1810-7. [CrossRef]
- Nigo M, Munita JM, Arias CA, Murray BE. What's new in the tre- atment of enterococcal endocarditis? Curr Infect Dis Rep. 2014; 16(10): 431. [CrossRef]
- Pericas JM, Cervera C, del Rio A, et al. Changes in the treatment of Enterococcus faecalis infective endocarditis in Spain in the last 15 years: from ampicillin plus gentamicin to ampicillin plus ceftri- axone. Clin Microbiol Infect. 2014; 20(12): O1075-83. [CrossRef]
- Fernández-Hidalgo N, Almirante B, Gavaldà J, et al. Ampicillin plus ceftriaxone is as effective as ampicillin plus gentamicin for treating enterococcus faecalis infective endocarditis. Clin Infect Dis. 2013; 56(9): 1261-8. [CrossRef]
- Gavaldà J, Len O, Miró JM, et al. Brief communication: treatment of Enterococcus faecalis endocarditis with ampicillin plus ceftria- xone. Ann Intern Med. 2007; 146(8): 574-9. [CrossRef]
- Cerón I, Muñoz P, Marín M, et al. Efficacy of daptomycin in the treat- ment of enterococcal endocarditis: a 5 year comparison with con- ventional therapy. J Antimicrob Chemother. 2014; 69(6): 1669-74. [CrossRef]
- Hall Snyder A, Werth BJ, Barber KE, Sakoulas G, Rybak MJ. Eva- luation of the novel combination of daptomycin plus ceftriaxone against vancomycin-resistant enterococci in an in vitro pharma- cokinetic/pharmacodynamic simulated endocardial vegetation model. J Antimicrob Chemother. 2014; 69(8): 2148-54. [CrossRef]
- Chang FY, Peacock JE Jr, Musher DM, et al. Staphylococcus aure- us bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine (Baltimore). 2003; 82(5): 333-9. [CrossRef]
- Kim SH, Kim KH, Kim HB, et al. Outcome of vancomycin treatment in patients with methicillin-susceptible Staphylococcus aureus bacte- remia. Antimicrob Agents Chemother. 2008; 52(1): 192-7. [CrossRef]
- Small PM, Chambers HF. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob Agents Che- mother. 1990; 34(6): 1227-31. [CrossRef]
- Lee S, Choe PG, Song KH, et al. Is cefazolin inferior to nafcillin for treatment of methicillin-susceptible Staphylococcus aureus bacteremia? Antimicrob Agents Chemother. 2011; 55(11): 5122- 6. [CrossRef]
- Nannini EC, Singh KV, Murray BE. Relapse of type A beta-lacta- mase-producing Staphylococcus aureus native valve endocardi- tis during cefazolin therapy: revisiting the issue. Clin Infect Dis. 2003; 37(9): 1194-8. [CrossRef]
- Nannini EC, Stryjewski ME, Singh KV, et al. Inoculum effect with cefazolin among clinical isolates of methicillin-susceptible Staphylococcus aureus: frequency and possible cause of cefazo- lin treatment failure. Antimicrob Agents Chemother. 2009; 53(8): 3437-41. [CrossRef]
- Paul M, Zemer-Wassercug N, Talker O, et al. Are all beta-lac- tams similarly effective in the treatment of methicillin-sensitive Staphylococcus aureus bacteraemia? Clin Microbiol Infect. 2011; 17(10): 1581-6. [CrossRef]
- Nannini EC, Stryjewski ME, Singh KV, et al. Determination of an inoculum effect with various cephalosporins among clinical isola- tes of methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother. 2010; 54(5): 2206-8. [CrossRef]
- Sonneville R, Mirabel M, Hajage D, et al. Neurologic complicati- ons and outcomes of infective endocarditis in critically ill pati- ents: the ENDOcardite en REAnimation prospective multicenter study. Crit Care Med. 2011; 39(6): 1474-81. [CrossRef]
- Snygg-Martin U, Gustafsson L, Rosengren L, et al. Cerebrovascu- lar complications in patients with left-sided infective endocarditis are common: a prospective study using magnetic resonance ima- ging and neurochemical brain damage markers. Clin Infect Dis. 2008; 47(1): 23-30. [CrossRef]
- Murray RJ. Staphylococcus aureus infective endocarditis: diagno- sis and management guidelines. Intern Med J. 2005; 35(Suppl. 2): S25-44. [CrossRef]
- van Hal SJ, Lodise TP, Paterson DL. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococ- cus aureus infections: a systematic review and meta-analysis. Clin Infect Dis. 2012; 54(6):755-71. [CrossRef]
- Moore CL, Osaki-Kiyan P, Haque NZ, Perri MB, Donabedian S, Zer- vos MJ. Daptomycin versus vancomycin for bloodstream infec- tions due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-cont- rol study. Clin Infect Dis. 2012; 54(1): 51-8. [CrossRef]
- Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of met- hicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis. 2011; 52(3): 285-92. [CrossRef]
- Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staph- ylococcus aureus. N Engl J Med. 2006; 355(7): 653-65. [CrossRef]
- Dohmen PM, Guleri A, Capone A, et al. Daptomycin for the treat- ment of infective endocarditis: results from a European registry. J Antimicrob Chemother. 2013; 68(4): 936-42. [CrossRef]
- Smith JR, Claeys KC, Barber KE, Rybak MJ. High-dose daptomy- cin therapy for staphylococcal endocarditis and when to apply it. Curr Infect Dis Rep. 2014; 16(10): 429. [CrossRef]
- Zainah H, Zervos M, Stephane W, Chamas Alhelo S, Alkhoury G, Weinmann A. Daptomycin failure for treatment of pulmonary septic emboli in native tricuspid and mitral valve methicillin-re- sistant Staphylococcus aureus endocarditis. Case Rep Infect Dis. 2013; 2013: 653582.
- Chambers HF, Sande MA. Teicoplanin versus nafcillin and van- comycin in the treatment of experimental endocarditis caused by methicillin-susceptible or -resistant Staphylococcus aureus. Anti- microb Agents Chemother. 1984; 26(1): 61-4. [CrossRef]
- de Górgolas M, Avilés P, Verdejo C, Fernández Guerrero ML. Treat- ment of experimental endocarditis due to methicillin-susceptible or methicillin-resistant Staphylococcus aureus with trimethop- rim-sulfamethoxazole and antibiotics that inhibit cell wall synthe- sis. Antimicrob Agents Chemother. 1995; 39(4): 953-7. [CrossRef]
- Kaatz GW, Seo SM, Dorman NJ, Lerner SA. Emergence of teicop- lanin resistance during therapy of Staphylococcus aureus endo- carditis. J Infect Dis. 1990; 162(1): 103-8. [CrossRef]
- Gilbert DN, Wood CA, Kimbrough RC. Failure of treatment with teicoplanin at 6 milligrams/kilogram/day in patients with Staph- ylococcus aureus intravascular infection. The Infectious Diseases Consortium of Oregon. Antimicrob Agents Chemother. 1991; 35(1): 79-87. [CrossRef]
- Ueda T, Takesue Y, Nakajima K, et al. High-dose regimen to ac- hieve novel target trough concentration in teicoplanin. J Infect Chemother. 2014; 20(1): 43-7. [CrossRef]
- Lee CH, Tsai CY, Li CC, Chien CC, Liu JW. Teicoplanin therapy for MRSA bacteraemia: a retrospective study emphasizing the im- portance of maintenance dosing in improving clinical outcomes. J Antimicrob Chemother. 2015; 70(1): 257-63. [CrossRef]
- Svetitsky S, Leibovici L, Paul M. Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta- analysis. Antimicrob Agents Chemother. 2009; 53(10): 4069-79.
- Finch G, Eliopoulos GM. Safety and efficacy of glycopeptide antibio- tics. J Antimicrob Chemother. 2005; 55(Suppl. 2): ii5-13. [CrossRef]
- Cosgrove SE, Vigliani GA, Fowler VG Jr, et al. Initial low-dose gen- tamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic. Clin Infect Dis. 2009; 48(6): 713-21. [CrossRef]
- Bashore TM, Cabell C, Fowler V Jr. Update on infective endocardi- tis. Curr Probl Cardiol. 2006; 31(4): 274-352. [CrossRef]
- Riedel DJ, Weekes E, Forrest GN.Addition of rifampin to standard therapy for treatment of native valve infective endocarditis cau- sed by Staphylococcus aureus. Antimicrob Agents Chemother. 2008; 52(7): 2463-7. [CrossRef]
- Cornely OA, Bassetti M, Calandra T, et al. ESCMID guideline for the diagnosis and management of Candida diseases 2012: non- neutropenic adult patients. Clin Microbiol Infect. 2012; 18(Suppl. 7): 19-37. [CrossRef]
- Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the Ameri- can Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharma- cists. Am J Health Syst Pharm. 2009; 66(1): 82-98. [CrossRef]
- Elyasi S, Khalili H, Dashti-Khavidaki S, Mohammadpour A. Van- comycin-induced nephrotoxicity: mechanism, incidence, risk fac- tors and special populations. A literature review. Eur J Clin Phar- macol. 2012; 68(9): 1243-55. [CrossRef]
- Verhagen DW, Hermanides J, Korevaar JC, et al. Prognostic value of serial C-reactive protein measurements in left-sided native val- ve endocarditis. Arch Intern Med. 2008; 168(3): 302-7. [CrossRef]
- Prendergast BD, Tornos P. Surgery for infective endocarditis: who and when? Circulation. 2010; 121(9): 1141-52. [CrossRef]
- Kang DH, Kim YJ, Kim SH, et al. Early surgery versus conven- tional treatment for infective endocarditis. N Engl J Med. 2012; 366(26): 2466-73. [CrossRef]
- Lalani T, Cabell CH, Benjamin DK, et al. Analysis of the impact of early surgery on in-hospital mortality of native valve endocardi- tis: use of propensity score and instrumental variable methods to adjust for treatment-selection bias. Circulation. 2010; 121(8): 1005-13. [CrossRef]
- Barsic B, Dickerman S, Krajinovic V, et al. Influence of the timing of cardiac surgery on the outcome of patients with infective endo- carditis and stroke. Clin Infect Dis. 2013; 56(2): 209-17. [CrossRef]
- Thuny F, Habib G. When should we operate on patients with acute infective endocarditis? Heart. 2010; 96(11): 892-7. [CrossRef]
- Misfeld M, Girrbach F, Etz CD, et al. Surgery for infective endocarditis complicated by cerebral embolism: a consecutive series of 375 pati- ents. J Thorac Cardiovasc Surg. 2014; 147(6): 1837-44. [CrossRef]
- Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideli- ne for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart As- sociation Task Force on Practice Guidelines. J Thorac Cardiovasc Surg. 2014; 148(1): e1-e132. [CrossRef]
- Delahaye F, Rial MO, de Gevigney G, Ecochard R, Delaye J. A criti- cal appraisal of the quality of the management of infective endo- carditis. J Am Coll Cardiol. 1999; 33(3): 788-93. [CrossRef]
- Botelho-Nevers E, Thuny F, Casalta JP, et al. Dramatic reduction in infective endocarditis-related mortality with a management-ba- sed approach. Arch Intern Med. 2009; 169(14): 1290-8. [CrossRef]
- Wilson W, Taubert KA, Gewitz M, et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fe- ver, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation. 2007; 116(15): 1736-54. [CrossRef]
- Richey R, Wray D, Stokes T; Guideline Development Group. Proph- ylaxis against infective endocarditis: summary of NICE guidance. Br Med J. 2008; 336(7647): 770-1.
- Duval X, Delahaye F, Alla F, et al. Temporal trends in infective en- docarditis in the context of prophylaxis guideline modifications: three successive population-based surveys. J Am Coll Cardiol. 2012; 59(22):1968-76. [CrossRef]
- Desimone DC, Tleyjeh IM, Correa de Sa DD, et al. Incidence of in- fective endocarditis caused by viridans group streptococci before and after publication of the 2007 American Heart Association's endocarditis prevention guidelines. Circulation. 2012; 126(1): 60-4. [CrossRef]
- Dayer MJ, Jones S, Prendergast B, Baddour LM, Lockhart PB, Thornhill MH. Incidence of infective endocarditis in England, 2000-13: a secular trend, interrupted time-series analysis. Lancet. 2015; 385(9974): 1219-28. [CrossRef]
- Duval X, Hoen B. Prophylaxis for infective endocarditis: let's end the debate. Lancet. 2015; 385(9974): 1164-5. [CrossRef]
- Fowler VG Jr, Olsen MK, Corey GR, et al. Clinical identifiers of complicated Staphylococcus aureus bacteremia. Arch Intern Med. 2003; 163(17): 2066-72. [CrossRef]
- Palraj BR, Baddour LM, Hess EP, et al. Predicting risk of endocardi- tis using a clinical tool (PREDICT): scoring system to guide use of echocardiography in the management of Staphylococcus aureus bacteremia. Clin Infect Dis. 2015; 61(1): 18-28. [CrossRef]
- Ekkelenkamp MB, van der Bruggen T, van de Vijver DA, Wolfs TF, Bonten MJ. Bacteremic complications of intravascular catheters colonized with Staphylococcus aureus. Clin Infect Dis. 2008; 46(1): 114-8. [CrossRef]
- Ruhe JJ, Menon A. Clinical significance of isolated Staphylococ- cus aureus central venous catheter tip cultures. Clin Microbiol Infect. 2006; 12(9): 933-6. [CrossRef]
- Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-rela- ted infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2009; 49(1): 1-45.
- van Eck van der Sluijs A, Oosterheert JJ, Ekkelenkamp MB, Hoe- pelman IM, Peters EJ. Bacteremic complications of intravascular catheter tip colonization with Gram-negative micro-organisms in patients without preceding bacteremia. Eur J Clin Microbiol In- fect Dis. 2012; 31(6): 1027-33. [CrossRef]
- Park KH, Kim SH, Song EH, et al. Development of bacteraemia or fungaemia after removal of colonized central venous catheters in patients with negative concomitant blood cultures. Clin Microbiol Infect. 2010; 16(6): 742-6. [CrossRef]
- Thomsen RW, Farkas DK, Friis S, et al. Endocarditis and risk of cancer: a Danish nationwide cohort study. Am J Med. 2013; 126(1): 58-67. [CrossRef]
| APA | YAVUZ ŞİMŞEK S (2015). İnfektif Endokardit: Güncel Bilgiler. , 46 - 67. |
| Chicago | YAVUZ ŞİMŞEK Serap İnfektif Endokardit: Güncel Bilgiler. (2015): 46 - 67. |
| MLA | YAVUZ ŞİMŞEK Serap İnfektif Endokardit: Güncel Bilgiler. , 2015, ss.46 - 67. |
| AMA | YAVUZ ŞİMŞEK S İnfektif Endokardit: Güncel Bilgiler. . 2015; 46 - 67. |
| Vancouver | YAVUZ ŞİMŞEK S İnfektif Endokardit: Güncel Bilgiler. . 2015; 46 - 67. |
| IEEE | YAVUZ ŞİMŞEK S "İnfektif Endokardit: Güncel Bilgiler." , ss.46 - 67, 2015. |
| ISNAD | YAVUZ ŞİMŞEK, Serap. "İnfektif Endokardit: Güncel Bilgiler". (2015), 46-67. |
| APA | YAVUZ ŞİMŞEK S (2015). İnfektif Endokardit: Güncel Bilgiler. Klimik Dergisi, 28(2), 46 - 67. |
| Chicago | YAVUZ ŞİMŞEK Serap İnfektif Endokardit: Güncel Bilgiler. Klimik Dergisi 28, no.2 (2015): 46 - 67. |
| MLA | YAVUZ ŞİMŞEK Serap İnfektif Endokardit: Güncel Bilgiler. Klimik Dergisi, vol.28, no.2, 2015, ss.46 - 67. |
| AMA | YAVUZ ŞİMŞEK S İnfektif Endokardit: Güncel Bilgiler. Klimik Dergisi. 2015; 28(2): 46 - 67. |
| Vancouver | YAVUZ ŞİMŞEK S İnfektif Endokardit: Güncel Bilgiler. Klimik Dergisi. 2015; 28(2): 46 - 67. |
| IEEE | YAVUZ ŞİMŞEK S "İnfektif Endokardit: Güncel Bilgiler." Klimik Dergisi, 28, ss.46 - 67, 2015. |
| ISNAD | YAVUZ ŞİMŞEK, Serap. "İnfektif Endokardit: Güncel Bilgiler". Klimik Dergisi 28/2 (2015), 46-67. |
